Sarcopenia Treatment Market Size
The global Sarcopenia Treatment market was valued at USD 3.36 billion in 2025 and is projected to reach USD 5.56 billion by 2033, growing at a CAGR of 5.8% during the forecast period from 2026 to 2033.
The market is witnessing steady growth due to the rapidly increasing aging population, rising prevalence of muscle degeneration disorders, and growing awareness regarding age-related frailty and mobility loss. Increasing healthcare expenditure, expanding geriatric care infrastructure, and rising focus on healthy aging programs are further contributing to market expansion globally.
Market growth is strongly supported by the increasing adoption of protein supplements, vitamin D therapies, hormonal treatments, physical rehabilitation programs, and emerging biologic therapies for muscle preservation and strength enhancement. Nutritional supplementation continues to dominate the treatment segment owing to growing awareness regarding preventive healthcare and muscle health maintenance among elderly populations. In addition, advancements in AI-based body composition analysis, digital rehabilitation platforms, and remote physiotherapy solutions are improving treatment accessibility and patient outcomes. Expanding home healthcare services and increasing integration of personalized nutrition programs are also accelerating market penetration across developed and emerging economies.
Recent clinical advancements and regulatory developments are strengthening the future outlook of the market. In 2025, multiple biotechnology companies advanced late-stage clinical trials for myostatin inhibitors and ActRII pathway-targeted therapies aimed at improving skeletal muscle mass and physical function in sarcopenia patients. Regulatory agencies including the U.S. Food and Drug Administration continue to encourage development of therapies targeting age-related muscle loss and frailty conditions through supportive clinical research frameworks. Pharmaceutical and nutraceutical companies are also increasing investments in high-protein medical nutrition products, anabolic therapies, and regenerative medicine solutions to address growing demand for sarcopenia management.
The future outlook for the Sarcopenia Treatment market remains positive, supported by advancements in precision medicine, increasing adoption of digital health technologies, and growing demand for preventive geriatric care solutions. Integration of wearable monitoring devices, AI-assisted mobility tracking systems, and personalized exercise management platforms is expected to improve treatment adherence and long-term patient outcomes. Furthermore, ongoing research involving stem cell therapies, gene-based muscle regeneration technologies, and next-generation biologics is likely to create significant growth opportunities for pharmaceutical, biotechnology, and healthcare companies over the coming years.
Sarcopenia Treatment Market Trends and Dynamics
The global sarcopenia treatment market has been fueled by factors such as an increase in the elderly population and increased acceptance of vitamins and dietary supplements. Furthermore, an increase in sarcopenia cases is expected to drive the growth of the sarcopenia treatment market. Furthermore, an increase in R&D activities for the treatment of sarcopenia is expected to drive the growth of the sarcopenia treatment market.
Increasing vitamin and malnutrition deficiency in underdeveloped countries will drive market growth.
In developing and underdeveloped countries, micronutrient-rich foods are consumed in low proportions, resulting in malnutrition. The most common cause of sarcopenia is malnutrition. Malnutrition is very common in Latin America, Africa, and Southeast Asia due to poor nutritional status. As malnutrition rates rise, so does the prevalence of sarcopenia, creating a high demand for sarcopenia treatment supplements. Vitamin D and B12 deficiency are common among vegetarians and the elderly, and it is the leading cause of sarcopenia. The rising prevalence of vitamin deficiency is expected to demand sarcopenia treatment supplements.
Furthermore, according to data from World Population Prospects(WPP): 1 in 6 people in the world will be over the age of 65 (16%) by 2050, up from 1 in 11 in 2019 (9%), and 1 in 4 people in Europe and Northern America will be 65 or older by 2050. Globally, people aged 65 and up outnumbered children under five in 2018. As a result, the number of people aged 80 and over is expected to treble between 2019 and 2050, from 143 million to 426 million. As a result of the growing aging population and growing interest in preventative healthcare, supplement adoption is on the rise, a major driver in increasing demand for sarcopenia treatment.
Moreover, sarcopenia is a very recurrent disease, but there are no effective treatment options. Sarcopenia is common in the elderly, so many pharmaceutical companies focus on the research and development of drugs to treat sarcopenia. Companies and organizations such as Novartis, Nestle, GSK, the European Working Group on Sarcopenia in Older People (EWGSOP), and the International Osteoporosis Organization are concentrating on research and development well as clinical trials for age-related muscle mass loss. Many pharmaceutical companies have shown positive clinical trial results for drug development. For example, Novartis AG announced in June 2017 the positive results of a 24-week randomized study of Bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. THE MANUFACTURER'S increased R&D activities are expected to fuel the opportunity for sarcopenia treatment market growth.
Low awareness about sarcopenia is likely to hamper market growth.
Sarcopenia is a common illness among orthopedic patients, and it is linked to an increased risk of falling, fractures, mortality, and hospital costs. The sarcopenia therapy market is hampered by a lack of awareness among the senior population, leading to poor diagnosis and treatment.Sarcopenia is also less well-known as a geriatric syndrome than dementia or falls, and it is frequently overlooked in normal aged care. At the same time, treatments for the ailment are still being developed.Furthermore, there are currently no licensed muscle-building drugs to treat sarcopenia in the United States; therefore, non-drug therapies such as exercise, physical therapy, lifestyle, and nutrition change are the sole options. As a result, the absence of effective medicines to treat the illness is a major issue limiting the market growth.
Sarcopenia Treatment Market Scope and Summary
| Metrics | Details |
| Market CAGR | 6% |
| Segments Covered | By Technology, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Sarcopenia Treatment Market Geographical Share
North America region holds the largest market share of global sarcopenia treatment market
North America is expected to hold a controlling position in the sarcopenia treatment market due to developed healthcare facilities and technological advancements, which are expected to fuel the market growth during the forecast period. According to the Population Reference Bureau, the number of Americans aged 65 and older is expected to nearly double from 52 million in 2018 to 95 million by 2060, with the 65-and-older age group accounting for 23% of the total population. Sarcopenia affects approximately 45 percent of older adults in the United States, and its prevalence is expected to rise as the population ages. Furthermore, the economic burden of sarcopenia-related healthcare expenditures in the United States is estimated to be USD 18.5 billion per year. Furthermore, the studied market growth in this region is likely to be driven by health awareness and the active presence of major players.
Key Developments
February 2026: Growing advancements in myostatin inhibitors and biologic therapies accelerated innovation in muscle-preserving treatments for sarcopenia and improved clinical outcomes.
January 2026: Increasing adoption of nutritional supplements including protein, vitamin D, and amino acid formulations strengthened first-line treatment approaches in sarcopenia management.
December 2025: Rising focus on healthy aging programs and geriatric care initiatives supported early diagnosis and preventive treatment strategies for age-related muscle loss.
November 2025: Expansion of digital diagnostics and AI-based muscle mass screening tools improved detection rates and enabled timely intervention in sarcopenia patients.
October 2025: Increasing prevalence of aging populations, sedentary lifestyles, and chronic diseases boosted demand for effective sarcopenia therapies globally.
September 2025: Growing integration of home-based care and telehealth nutrition services enhanced patient adherence and long-term management of sarcopenia.
August 2025: Rising investments in clinical research and novel drug pipelines, including ActRII pathway therapies, accelerated development of advanced sarcopenia treatment solutions.
July 2025: Increasing collaborations between pharmaceutical and nutrition companies supported innovation in combination therapies integrating diet, exercise, and pharmacological interventions for sarcopenia treatment.
Sarcopenia Treatment Market Companies and Competitive Landscape
To improve product penetration, the major players in the sarcopenia therapy market have been focusing on new marketing and sales techniques. In addition, the growing preference for online distribution channels has played a significant influence. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Pfizer Inc, GlaxoSmithKline Plc ,Nestle SA, Sanofi SA, Bayer AG, Amway, Cadila Healthcare Ltd, Eli Lilly and Company.
GlaxoSmithKline PLC
Overview: GlaxoSmithKline PLC is a multinational pharmaceutical company. Pharmaceuticals, Vaccines, and Consumer Healthcare are the three core areas where the company conducts research and development. Tablets, creams/ointments, inhalers, injections, liquids, and sterile items are among the company's product compositions. Its Pharmaceuticals division offers a range of well-known drugs in respiratory, HIV, immuno-inflammation, and oncology. Its Vaccines division provides a vaccination portfolio that can help people defend themselves from various diseases throughout their lifetimes. Pneumococcal illness, meningitis, hepatitis, rotavirus, whooping cough, and influenza are addressed by its vaccinations. Its Consumer Healthcare division blends science and consumer insights to provide everyday healthcare products that consumers trust and that professionals suggest for oral health, pain relief, cold, flu, allergy relief, digestive health, vitamins, minerals, and supplements.
Product Portfolio:
Centrum : Centrum multivitamin and mineral products include up to 26 vital components to address the nutritional needs of children and adults. Centrum also has several specialist formulations that help with energy, immunity, metabolism, eye, heart, bone, and brain health.
